Join the club for FREE to access the whole archive and other member benefits.

Andrew Dunn

Biopharma correspondent

Andrew Dunn is a senior biopharma correspondent, focused on uncovering and explaining the future of the biotech and pharmaceutical industries. His reporting interests include AI's emerging role in biotech, cell and gene therapy, and how money and medicine mix. Based in New York City, he joined Endpoints News in 2023, previously reporting on biotech at Business Insider and BioPharma Dive. His work has been cited by news outlets including the Washington Post, CNN, and the New York Times. He’s also appeared on CNBC, C-SPAN, and MSNBC to discuss his work. Dunn graduated from the University of Maryland, College Park, majoring in journalism and economics. 

Visit website: https://endpts.com/author/andrew-dunn/

 andrew-dunn-176a9379

 AndrewE_Dunn

See also

Endpoints News

News provider covering bipharma’s most comprehensive daily news and updates

Details last updated 15-Dec-2024

Articles written by Andrew Dunn

Recursion overhauls pipeline after key drug fails in mid-stage trial

Recursion overhauls pipeline after key drug fails in mid-stage trial

Endpoints News - 05-May-2025

With $509M in cash, biotech bets on fewer, stronger programs ahead of 2025 data

Stately Bio emerges with AI-powered window into living cells

Stately Bio emerges with AI-powered window into living cells

Endpoints News - 01-May-2025

AI startup decodes live cell behaviour using simple imaging and machine learning

Tuning the future: epigenetic editing breaks new ground in genetic medicine

Tuning the future: epigenetic editing breaks new ground in genetic medicine

Endpoints News - 12-Jan-2025

Tune Therapeutics secures $175M to pioneer precise gene modulation therapies

Isomorphic Labs rethinks drug discovery with no labs, just AI

Isomorphic Labs rethinks drug discovery with no labs, just AI

Endpoints News - 12-Dec-2024

This aims to reduce development time but faces challenges in proving real-world success

Iambic’s enchant AI aims to bridge the gap between lab and clinic

Iambic’s enchant AI aims to bridge the gap between lab and clinic

Endpoints News - 29-Oct-2024

New AI model enhances drug success with precise predictions